E. Ohman J or Asset Management AB Sells 9,174 Shares of DexCom, Inc. $DXCM

E. Ohman J or Asset Management AB decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.1% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 104,030 shares of the medical device company’s stock after selling 9,174 shares during the period. E. Ohman J or Asset Management AB’s holdings in DexCom were worth $8,977,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in DXCM. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after buying an additional 1,515,702 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of DexCom during the second quarter valued at about $173,237,000. Janus Henderson Group PLC increased its position in shares of DexCom by 32.3% during the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock valued at $166,077,000 after buying an additional 645,534 shares during the period. Deutsche Bank AG purchased a new stake in shares of DexCom in the second quarter worth about $164,035,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of DexCom by 100.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock worth $159,832,000 after buying an additional 1,275,142 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 2.4%

Shares of NASDAQ:DXCM opened at $78.32 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $87.03 and a two-hundred day simple moving average of $76.53. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59. The stock has a market capitalization of $29.55 billion, a price-to-earnings ratio of 31.48, a PEG ratio of 1.34 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.48 earnings per share. On average, research analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, Director Nicholas Augustinos sold 6,539 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $549,537.56. Following the completion of the sale, the director directly owned 29,293 shares in the company, valued at $2,461,783.72. The trade was a 18.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme M. Sylvain sold 3,638 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the sale, the executive vice president owned 146,828 shares of the company’s stock, valued at $12,226,367.56. This trade represents a 2.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 24,257 shares of company stock worth $2,049,173. Company insiders own 0.28% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. UBS Group set a $96.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Tuesday, July 28th. Truist Financial set a $102.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Friday, September 18th. JPMorgan Chase & Co. increased their target price on shares of DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a research note on Friday, July 31st. Robert W. Baird set a $105.00 target price on DexCom in a research report on Friday, July 31st. Finally, Mizuho set a $100.00 price target on DexCom in a research report on Tuesday, October 13th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $92.43.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.